Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Johnson & Johnson (JNJ – Research Report), Eli Lilly & Co (LLY – Research Report) and Coherus Biosciences (CHRS – Research Report).
Johnson & Johnson (JNJ)
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Hold rating on Johnson & Johnson, with a price target of $163.00. The company’s shares closed last Friday at $154.64.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of
Johnson & Johnson has an analyst consensus of Moderate Buy, with a price target consensus of $174.00.
See the top stocks recommended by analysts >>
Eli Lilly & Co (LLY)
Barclays analyst Carter Gould assigned a Buy rating to Eli Lilly & Co today and set a price target of $913.00. The company’s shares closed last Friday at $770.00, close to its 52-week high of $800.78.
According to TipRanks.com, Gould is a 4-star analyst with an average return of
Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $881.00, a 14.0% upside from current levels. In a report issued on May 8, Berenberg Bank also maintained a Buy rating on the stock with a $850.00 price target.
Coherus Biosciences (CHRS)
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Coherus Biosciences, with a price target of $7.00. The company’s shares closed last Friday at $2.12, close to its 52-week low of $1.43.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of
Coherus Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $9.20, implying a 322.0% upside from current levels. In a report issued on May 10, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on JNJ:
- Ex-Dividend Date Nearing for These 10 Stocks – Week of May 20, 2024
- Johnson & Johnson to acquire Proteologix for $850M in cash
- Nanobiotix announces FDA issuance of Study May Proceed Letter for NBTXR3 study
- Johnson & Johnson Will Sell Remaining Stake in Kenvue (NYSE:KVUE)
- Kenvue confirms launch of 182.33M secondary offering for holders
